Results 191 to 200 of about 8,764,093 (218)

Chemically and Biologically Engineered Bacteria‐Based Delivery Systems for Emerging Diagnosis and Advanced Therapy

Advances in Materials, 2021
Bacteria are one of the main groups of organisms, which dynamically and closely participate in human health and disease development. With the integration of chemical biotechnology, bacteria have been utilized as an emerging delivery system for various ...
Zhao-Ting Li, Yixin Wang, Jun Liu, Piper A. Rawding, J. Bu, Seungpyo Hong, Quanyin Hu   +6 more
semanticscholar   +1 more source

Predictors and potential advantages of PERT and advanced therapy use in acute pulmonary embolism

Catheterization and cardiovascular interventions, 2021
We sought to examine predictors of pulmonary embolism response team (PERT) utilization and identify those who could benefit from advanced therapy.
M. Parikh, Nicole Chahine, T. Hammad, Leben Tefera, Jun Li, T. Carman, R. Schilz, M. Shishehbor   +7 more
semanticscholar   +1 more source

Expediting Drug Development: FDA’s New Regenerative Medicine Advanced Therapy Designation

Therapeutic Innovation and Regulatory Science, 2019
In March 2017, the US FDA introduced the new Regenerative Medicine Advanced Therapy (RMAT) designation thus recognizing the enormous potential of these medicines and the need for efficient regulatory tools to accelerate their development and their ...
Annegret Vaggelas, D. Seimetz
semanticscholar   +1 more source

Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.

Advances in Experimental Medicine and Biology, 2023
M. Schuessler-Lenz, C. Herberts, I. Reischl, S. Ruiz, P. Celis, C. Beuneu, R. Kjeken, M. Timón   +7 more
semanticscholar   +1 more source

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.

New England Journal of Medicine
BACKGROUND Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes the degradation of mutated p110α.
N. Turner, Seock-Ah Im, C. Saura, D. Juric, S. Loibl, K. Kalinsky, P. Schmid, S. Loi, P. Sunpaweravong, A. Musolino, Hui-Ping Li, Qingyuan Zhang, Z. Nowecki, R. Leung, E. Thanopoulou, N. Shankar, G. Lei, T. Stout, K. Hutchinson, J. Schutzman, Chunyan Song, K. Jhaveri   +21 more
semanticscholar   +1 more source

Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians

Ca-A Cancer Journal for Clinicians, 2022
Travis C Salzillo, William A Hal, Christopher Schultz   +2 more
exaly  

Advanced Therapy Biomanufacturing as a Service

GEN Edge, 2022
V. Raper
semanticscholar   +1 more source

Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Hope Rugo, Özge Gümüşay, Laura A Huppert   +2 more
exaly  

Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis

Oncologist, 2021
Qing Liu, Yuan-Hong Gao, Weiwei Xiao
exaly  

Treatment of muscle-invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
William K. Oh, Matthew D Galsky, Vaibhav G Patel   +2 more
exaly